Throughout his 50+ year career as a healthcare practitioner, administrator, and innovator, Dr. Franklyn Prendergast has greatly influenced the direction of healthcare and medical sciences research in the United States and around the globe. In recent years, he turned his attention to healthcare in the GCC, providing strategic guidance to the Saudi Ministry of Health and serving as a keynote speaker for the Ministry’s National Healthcare Strategy and Health System Design conferences held in 2014.
In 2015, Dr. Franklyn Prendergast retired from the Mayo Clinic in Rochester, Minnesota, the first and largest integrated nonprofit medical group practice in the world, where he most recently served as Professor in the Department of Molecular Pharmacology & Experimental Therapeutics. Franklyn held numerous leadership positions during his time at Mayo, including Director of the Mayo Clinic Comprehensive Cancer Center, Director of the Mayo Clinic Center for Individualized Medicine, and Chair of the Department of Biochemistry and Molecular Biology, among other roles. He also served on the Mayo Clinic Board of Trustees and the Mayo Foundation Executive Committee.
Currently, Franklyn is a member of the Board of Directors for Eli Lilly, Cancer Genetics, Inc., and the Infectious Disease Research Institute (IDRI), in addition to other organizations. He has also worked extensively with the National Institutes of Health, Board of Advisors for Division of Research Grants; the Board of Scientific Advisors of National Cancer Institute; and the National Cancer Advisory Board.
A former Rhodes scholar, Franklyn earned his BA and his MA from Oxford University. He then went on to receive his MD from the University of the West Indies, and his PhD from the University of Minnesota.